The Sarcopenia Treatment Market size is estimated at USD 3.15 billion in 2024, and is expected to reach USD 3.93 billion by 2029, growing at a CAGR of 4.58% during the forecast period (2024-2029).
The outbreak of COVID-19 had a significant impact on the sarcopenia treatment market during early pandemic. Additionally, many patients witnessed issues associated with sarcopenia during COVID-19, which increased the demand for sarcopenia treatment during COVID-19. For instance, according to a study published in July 2022 in the Frontier journal, Sarcopenia was frequently observed in patients with COVID-19, with varying prevalence, and the patients with COVID-19 were at increased risk of acute sarcopenia. Thus, due to the elevated risk of sarcopenia cases in COVID-19-infected patients, the demand for sarcopenia treatment increased during the pandemic.
However, the market is currently expected to witness stable growth due to the increased musculoskeletal problems acquired in post-COVID-19 patients and the rise in research and development of sarcopenia treatment products. Additionally, in the post-pandemic situation, malnutrition was found to be a common condition among geriatric COVID-19 survivors, and the demand for sarcopenia products is likely to rise, which is expected to fuel the market growth of the market studied over the coming years.
Factors such as the rise in the geriatric population and the increase in malnutrition, coupled with vitamin deficiency globally, are expected to increase the need for sarcopenia treatment, fueling the market growth over the study period. For instance, according to a study published in August 2022 in Nutrients Journal, older people had a higher risk of developing sarcopenia, emphasizing the need for proper treatment and nutrition intake. Moreover, according to the World Population Prospects 2022 report by the United Nations, the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. As the geriatric population is more prone to acquiring muscle issues due to their age, the demand for sarcopenia treatment is likely to rise with the aging population, thereby contributing to market growth over the study period.
Additionally, an increase in research studies and pipeline assets by the key players focusing on sarcopenia treatment is expected to augment the market growth over the study period. For instance, in May 2021, China Medical University Hospital sponsored a clinical trial to assess the effect of different post-exercise oral nutritional supplement intake timing on sarcopenia indicators in hemodialysis patients. Thus, owing to such clinical studies to understand the impact of nutritional supplements in various diseases, including sarcopenia, are expected to contribute to market growth over the forecast period.
Furthermore, a low-quality diet and muscle weakness are significant factors contributing to sarcopenia. Increasing the uptake of proper nutrition and vitamins may significantly reduce the risk of sarcopenia. For instance, according to a study published in April 2021 in Frontiers journal, consumption of polyunsaturated fat, monounsaturated fat, copper, vitamin E, omega-3, magnesium, iron, pyridoxine (B6), sodium, and caffeine are likely to decrease the chance of sarcopenia. Hence, such research studies depicting the importance of nutritional intake in treating sarcopenia are expected to drive market growth over the forecast period.
Thus, due to the increase in the geriatric population, the rise in research studies to develop sarcopenia treatment products and the surge in advantages offered by sarcopenia treatment products, the market studied is expected to witness significant growth over the study period. However, the non-availability of new drugs is expected to hinder the market's growth over the forecast period.
The growing research and development activities are helping in identifying the protein dosage required to fulfill the protein deficiency in the body, and treating sarcopenia is likely to drive segment growth. For instance, a study published in February 2021 in PubMed stated that higher dietary protein of up to 1.2 g/kg body weight/day might help prevent sarcopenia and maintain musculoskeletal health in older individuals. Whey and soy protein are the most common high-quality proteins, and there is growing consumer demand for additional plant-sourced dietary protein options.
Furthermore, according to the study published in March 2022 in PubMed, protein supplementation combined with exercise provides additional benefits on lower-extremity strength in healthy older adults with sarcopenia in Asian countries. Hence, studies demonstrating the use of protein supplements in sarcopenia are expected to drive market growth over the forecast period. Moreover, strategic activities by the key players and awareness regarding the importance of sarcopenia treatments are expected to boost market growth. For instance, in July 2022, World Sarcopenia Day is celebrated worldwide, and it serves as an opportunity to raise awareness and knowledge for the prevalent disease, sarcopenia.
Additionally, in March 2022, MusclePharm Corporation, a global provider of sports nutrition and lifestyle-branded nutritional supplements, expanded its ready-to-drink protein category by launching its new whey protein drink line in the summer of 2022. The new high-protein beverage line was marketed under the leading MusclePharm brand and contained over 20g of protein.
Hence, due to the increase in research and development and the key players' strategic activities, the studied segment is expected to witness significant growth over the forecast period.
Furthermore, an increase in the geriatric population in North America is expected to bolster market growth over the forecast period. For instance, according to the Statistics Canada July 2022 update, as of July 2022, almost one in five Canadians (18.8% of the population; 7,329,910 people) were at least 65 years of age. Thus, the geriatric population is more prone to sarcopenia and other muscle-related diseases; the rise in the geriatric population is expected to increase the need for sarcopenia treatment driving the market growth over the forecast period.
Furthermore, various clinical studies are widely conducted in the North American region to demonstrate the efficacy of supplements in sarcopenia treatments. For instance, in April 2022, the University of Arkansas sponsored a clinical trial to characterize skeletal muscle amino acid kinetics to an EAA challenge, i.e., an oral amino acid tolerance test (OATT), to determine the state of muscle health. For that purpose, trial subjects were given 10 g of a commercially available nutritional supplement for sarcopenia. Hence, an increase in such clinical studies demonstrating the clinical outcome of supplements to treat sarcopenia may result in the launch of new supplements and thus may contribute to the growth of the studied market in the region.
Moreover, various government initiatives support research and development of sarcopenia treatments, further contributing to market growth. For instance, according to the article published in February 2022 in PubMed, the US Department of Health and Human Services was one of the leading funding organizations that sponsored 1,604 sarcopenia-related articles. The United States is one of the top countries in the North American region that contributes more toward sarcopenia-related research and development. This increased research is anticipated to lead to various innovations in the country, driving the growth of the sarcopenia treatment market in the country.
Thus, due to the increase in the geriatric population and the rise in strategic activities by the government and key players, North America is expected to witness significant growth over the forecast period.
This product will be delivered within 2 business days.
The outbreak of COVID-19 had a significant impact on the sarcopenia treatment market during early pandemic. Additionally, many patients witnessed issues associated with sarcopenia during COVID-19, which increased the demand for sarcopenia treatment during COVID-19. For instance, according to a study published in July 2022 in the Frontier journal, Sarcopenia was frequently observed in patients with COVID-19, with varying prevalence, and the patients with COVID-19 were at increased risk of acute sarcopenia. Thus, due to the elevated risk of sarcopenia cases in COVID-19-infected patients, the demand for sarcopenia treatment increased during the pandemic.
However, the market is currently expected to witness stable growth due to the increased musculoskeletal problems acquired in post-COVID-19 patients and the rise in research and development of sarcopenia treatment products. Additionally, in the post-pandemic situation, malnutrition was found to be a common condition among geriatric COVID-19 survivors, and the demand for sarcopenia products is likely to rise, which is expected to fuel the market growth of the market studied over the coming years.
Factors such as the rise in the geriatric population and the increase in malnutrition, coupled with vitamin deficiency globally, are expected to increase the need for sarcopenia treatment, fueling the market growth over the study period. For instance, according to a study published in August 2022 in Nutrients Journal, older people had a higher risk of developing sarcopenia, emphasizing the need for proper treatment and nutrition intake. Moreover, according to the World Population Prospects 2022 report by the United Nations, the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. As the geriatric population is more prone to acquiring muscle issues due to their age, the demand for sarcopenia treatment is likely to rise with the aging population, thereby contributing to market growth over the study period.
Additionally, an increase in research studies and pipeline assets by the key players focusing on sarcopenia treatment is expected to augment the market growth over the study period. For instance, in May 2021, China Medical University Hospital sponsored a clinical trial to assess the effect of different post-exercise oral nutritional supplement intake timing on sarcopenia indicators in hemodialysis patients. Thus, owing to such clinical studies to understand the impact of nutritional supplements in various diseases, including sarcopenia, are expected to contribute to market growth over the forecast period.
Furthermore, a low-quality diet and muscle weakness are significant factors contributing to sarcopenia. Increasing the uptake of proper nutrition and vitamins may significantly reduce the risk of sarcopenia. For instance, according to a study published in April 2021 in Frontiers journal, consumption of polyunsaturated fat, monounsaturated fat, copper, vitamin E, omega-3, magnesium, iron, pyridoxine (B6), sodium, and caffeine are likely to decrease the chance of sarcopenia. Hence, such research studies depicting the importance of nutritional intake in treating sarcopenia are expected to drive market growth over the forecast period.
Thus, due to the increase in the geriatric population, the rise in research studies to develop sarcopenia treatment products and the surge in advantages offered by sarcopenia treatment products, the market studied is expected to witness significant growth over the study period. However, the non-availability of new drugs is expected to hinder the market's growth over the forecast period.
Sarcopenia Treatment Market Trends
Protein Supplement Anticipated to Show Considerable Growth During the Forecast Period
Protein is a critical macronutrient for the maintenance of normal bodily functions. Daily protein intake varies by age, sex, and degree of daily activity but is essential to maintaining muscle mass and strength throughout an individual's lifespan. Therefore, increasing protein intake in the diet prevents the loss of muscle mass, thus driving the market.The growing research and development activities are helping in identifying the protein dosage required to fulfill the protein deficiency in the body, and treating sarcopenia is likely to drive segment growth. For instance, a study published in February 2021 in PubMed stated that higher dietary protein of up to 1.2 g/kg body weight/day might help prevent sarcopenia and maintain musculoskeletal health in older individuals. Whey and soy protein are the most common high-quality proteins, and there is growing consumer demand for additional plant-sourced dietary protein options.
Furthermore, according to the study published in March 2022 in PubMed, protein supplementation combined with exercise provides additional benefits on lower-extremity strength in healthy older adults with sarcopenia in Asian countries. Hence, studies demonstrating the use of protein supplements in sarcopenia are expected to drive market growth over the forecast period. Moreover, strategic activities by the key players and awareness regarding the importance of sarcopenia treatments are expected to boost market growth. For instance, in July 2022, World Sarcopenia Day is celebrated worldwide, and it serves as an opportunity to raise awareness and knowledge for the prevalent disease, sarcopenia.
Additionally, in March 2022, MusclePharm Corporation, a global provider of sports nutrition and lifestyle-branded nutritional supplements, expanded its ready-to-drink protein category by launching its new whey protein drink line in the summer of 2022. The new high-protein beverage line was marketed under the leading MusclePharm brand and contained over 20g of protein.
Hence, due to the increase in research and development and the key players' strategic activities, the studied segment is expected to witness significant growth over the forecast period.
North America Anticipated to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant position in the sarcopenia treatment market, owing to the presence of developed healthcare facilities and technological advancements that are likely to fuel the growth of the sarcopenia treatment market during the forecast period.Furthermore, an increase in the geriatric population in North America is expected to bolster market growth over the forecast period. For instance, according to the Statistics Canada July 2022 update, as of July 2022, almost one in five Canadians (18.8% of the population; 7,329,910 people) were at least 65 years of age. Thus, the geriatric population is more prone to sarcopenia and other muscle-related diseases; the rise in the geriatric population is expected to increase the need for sarcopenia treatment driving the market growth over the forecast period.
Furthermore, various clinical studies are widely conducted in the North American region to demonstrate the efficacy of supplements in sarcopenia treatments. For instance, in April 2022, the University of Arkansas sponsored a clinical trial to characterize skeletal muscle amino acid kinetics to an EAA challenge, i.e., an oral amino acid tolerance test (OATT), to determine the state of muscle health. For that purpose, trial subjects were given 10 g of a commercially available nutritional supplement for sarcopenia. Hence, an increase in such clinical studies demonstrating the clinical outcome of supplements to treat sarcopenia may result in the launch of new supplements and thus may contribute to the growth of the studied market in the region.
Moreover, various government initiatives support research and development of sarcopenia treatments, further contributing to market growth. For instance, according to the article published in February 2022 in PubMed, the US Department of Health and Human Services was one of the leading funding organizations that sponsored 1,604 sarcopenia-related articles. The United States is one of the top countries in the North American region that contributes more toward sarcopenia-related research and development. This increased research is anticipated to lead to various innovations in the country, driving the growth of the sarcopenia treatment market in the country.
Thus, due to the increase in the geriatric population and the rise in strategic activities by the government and key players, North America is expected to witness significant growth over the forecast period.
Sarcopenia Treatment Industry Overview
The sarcopenia treatment market is moderately competitive in nature. The key manufacturers in the sarcopenia treatment market have been focusing on a clinical study to strengthen portfolios for the treatment of sarcopenia. A few key market players in the market studied are GSK PLC, Metagenics LLC, Nestlé SA, Sanofi SA, and Bayer AG.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Nutrition
- GSK PLC
- Nestle Health Science
- Sanofi SA
- Bayer AG
- Novartis AG
- Metagenics LLC
- Wellona Pharma
- Intas Pharmaceuticals Ltd
- Perrigo Company PLC
- Dr. Jockers Store
Methodology
LOADING...
